Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in NSCLC with Uncommon EGFR Mutations
NCT03434418Phase 2Completed
- Sponsor
- Duke University
- Start
- Jun 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03434418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434418.